Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Regorafenib is an oral multi-kinase inhibitor used as salvage therapy for metastatic colorectal cancer (mCRC). We tested whether serum cytokine levels are associated with clinical outcome in the mCRC patients receiving regorafenib. Serum samples were collected before treatment start, day 21, and pro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Suenaga, Mitsukuni, Mashima, Tetsuo, Kawata, Naomi, Wakatsuki, Takeru, Horiike, Yuki, Matsusaka, Satoshi, Dan, Shingo, Shinozaki, Eiji, Seimiya, Hiroyuki, Mizunuma, Nobuyuki, Yamaguchi, Kensei, Yamaguchi, Toshiharu
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085191/
https://ncbi.nlm.nih.gov/pubmed/27166185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9187
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars